Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Clinical efficacy across patient groups

All subgroups studied​​​​​​​ Visceral disease Bone-only disease Elderly Pre-/peri-menopausal
In 1st line with letrozole
In an updated non-prespecified PFS analysis of PALOMA-2, 1st line IBRANCE + letrozole demonstrated PFS improvements vs placebo + letrozole in patients with visceral metastases, including lung and liver*†2
  • In PALOMA-2, 48.2% of patients treated with IBRANCE + letrozole had visceral disease, which included lung and liver2

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Rugo H, et al. 2019.2 and IBRANCE Data on File.3
Data cut-off date: May 31, 2017.
*Evaluated according to RECIST Version 1.1.Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE + letrozole arm.2

In 1st or later line with fulvestrant

In PALOMA-3, IBRANCE + fulvestrant in 1st line or later demonstrated PFS improvements vs placebo + fulvestrant in patients with visceral metastases, including lung and liver*5

  • In PALOMA-3, 58% of patients treated with IBRANCE + fulvestrant had visceral disease, which included lung and liver†5

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Turner NC, et al. 2018.5
Data cut-off date: 23 October, 2015.
*Evaluated according to RECIST Version 1.1.Visceral disease included liver, lung, pleura, peritoneum, and/or brain metastases. ​​​​​​​

CI = confidence interval; FUL = fulvestrant; HR = hazard ratio; LET = letrozole; n = number of patients; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.

​​​​​​​References  
  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021
  2. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
  3. IBRANCE Data on File.
  4. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  5. Turner NC, et al. Ann Oncol. 2018;29(3):669-680.
  6. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.

​​​​​​​

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.